Edges in Network
| Network | GSE16446_top500tf - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | TAF5L |
| Upstream (Parents) |
|---|
| (<<) ZNF165 → TAF5L |
| (<<) E2F8 → TAF5L |
| (<<) RUNX1T1 → TAF5L |
| (<<) ZEB1 → TAF5L |
| (<<) ZNF367 → TAF5L |
| (<<) PRRX1 → TAF5L |
| (<<) RUNX2 → TAF5L |
| (<<) TSC22D3 → TAF5L |
| (<<) RB1 → TAF5L |
| (<<) BCL6 → TAF5L |
| (<<) TFAM → TAF5L |
| (<<) PTTG1 → TAF5L |
| (<<) MYBL2 → TAF5L |
| (<<) TAF5 → TAF5L |
| (<<) MAX → TAF5L |
| (<<) ELK3 → TAF5L |
| (<<) NOLC1 → TAF5L |
| Downstream (Children) |
|---|
| TAF5L → HOPX (>>) |
| TAF5L → CEBPA (>>) |
| TAF5L → ISL1 (>>) |
| TAF5L → CTNNB1 (>>) |
| TAF5L → ALX1 (>>) |
| TAF5L → PPARD (>>) |
| TAF5L → VAX2 (>>) |
| TAF5L → MYNN (>>) |
| TAF5L → PURB (>>) |
| TAF5L → CCRN4L (>>) |
| TAF5L → NR2C2 (>>) |
| TAF5L → RARB (>>) |
